Epigral Limited

NSEI:EPIGRAL 株式レポート

時価総額：₹52.4b

Epigral 過去の業績

過去 基準チェック /26

Epigralは、平均年間10.8%の収益成長を遂げていますが、 Chemicals業界の収益は、年間 成長しています。収益は、平均年間7.2% 13%収益成長率で 成長しています。 Epigralの自己資本利益率は16.1%であり、純利益率は14%です。

主要情報

10.84%

収益成長率

10.04%

EPS成長率

Chemicals 業界の成長17.68%
収益成長率12.98%
株主資本利益率16.08%
ネット・マージン13.97%
次回の業績アップデート02 May 2026

最近の業績更新

Recent updates

EPIGRAL: Steady ₹2,000 View Ahead Of 2026 Postal Ballot Outcome

Epigral's analyst fair value estimate is maintained at ₹2,000, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, as analysts fine tune their model inputs rather than changing their core view on the stock. What's in the News Epigral has scheduled a Special or Extraordinary Shareholders Meeting on May 19, 2026, to be conducted via postal ballot in India (Key Developments).

EPIGRAL: Steady ₹2,000 View Will Await Q3 Board Outcome

Analysts now keep Epigral's fair value estimate broadly unchanged at about ₹2,000 per share, with only minor tweaks to discount rate, revenue growth, profit margin and future P/E assumptions. This signals a largely steady view on the stock's valuation drivers.

EPIGRAL: Steady ₹2,000 Outlook Will Anticipate Q3 Board Meeting Outcome

Analysts have kept Epigral's fair value estimate steady at ₹2,000, with only minor tweaks to the discount rate, revenue growth, profit margin assumptions and future P/E supporting an unchanged price target. What's in the News A board meeting is scheduled on January 30, 2026 to consider the unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, along with the limited review report.

EPIGRAL: Steady ₹2,000 Fair Value Will Anticipate Q3 Board Review Outcome

Analysts have kept Epigral’s fair value estimate steady at ₹2,000, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects fine tuning of their models rather than a material change in conviction.

EPIGRAL: Reaffirmed ₹2,000 Fair Value Will Support Future Repricing

Analysts have maintained Epigral's fair value estimate at ₹2,000. A slightly lower assumed future P/E and a marginally higher discount rate together support this unchanged price target.

EPIGRAL: New CFO And Reaffirmed Fair Value Will Support Future Repricing

Analysts now see fair value for Epigral at ₹2,000.00 per share, with the unchanged target based on updated assumptions on discount rate, revenue growth, profit margin and future P/E that together reflect a recalibration of their long term earnings and valuation framework. What's in the News A board meeting is scheduled on January 30, 2026 to consider unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, along with the limited review report from statutory auditors (company filing).

EPIGRAL: New CFO And Reaffirmed Fair Value Will Support Future Repricing

Analysts have maintained Epigral's fair value estimate at ₹2,000 after updating their assumptions for discount rate, revenue growth, profit margin and future P/E. These revisions support a recalibrated price target narrative rather than a change in the overall valuation direction.

EPIGRAL: New CFO Appointment Is Expected To Strengthen Future Financial Governance

Analysts have cut their price target on Epigral from ₹2,600 to ₹2,000, citing updated assumptions that combine slightly higher revenue growth and profit margins with a lower future P/E multiple. What's in the News Epigral appointed Mr. Rakesh Agrawal as Chief Financial Officer and Key Managerial Personnel, effective 10 November 2025, following a board decision based on the Nomination and Remuneration Committee's recommendation (Key Developments).

Returns On Capital At Epigral (NSE:EPIGRAL) Have Hit The Brakes

Dec 26
Returns On Capital At Epigral (NSE:EPIGRAL) Have Hit The Brakes

Downgrade: What You Need To Know About The Latest Epigral Limited (NSE:EPIGRAL) Forecasts

Nov 16
Downgrade: What You Need To Know About The Latest Epigral Limited (NSE:EPIGRAL) Forecasts

Epigral Limited Just Missed Earnings - But Analysts Have Updated Their Models

Nov 13
Epigral Limited Just Missed Earnings - But Analysts Have Updated Their Models

If EPS Growth Is Important To You, Epigral (NSE:EPIGRAL) Presents An Opportunity

Nov 11
If EPS Growth Is Important To You, Epigral (NSE:EPIGRAL) Presents An Opportunity

Epigral (NSE:EPIGRAL) Has A Pretty Healthy Balance Sheet

Sep 28
Epigral (NSE:EPIGRAL) Has A Pretty Healthy Balance Sheet

Capacity Expansion And Green Energy Will Unlock Global Opportunities

The increase in Epigral’s consensus analyst price target to ₹2600 primarily reflects higher anticipated future earnings multiples, as indicated by the rise in future P/E, while the discount rate remains stable. What's in the News Upcoming board meeting to consider un-audited Q1 FY26 results and review fund-raising proposals via debt instruments.

Epigral Limited Just Recorded A 98% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 06
Epigral Limited Just Recorded A 98% EPS Beat: Here's What Analysts Are Forecasting Next

Epigral Limited (NSE:EPIGRAL) Might Not Be As Mispriced As It Looks

Jul 30
Epigral Limited (NSE:EPIGRAL) Might Not Be As Mispriced As It Looks

Investors Should Be Encouraged By Epigral's (NSE:EPIGRAL) Returns On Capital

Jun 02
Investors Should Be Encouraged By Epigral's (NSE:EPIGRAL) Returns On Capital

Subdued Growth No Barrier To Epigral Limited (NSE:EPIGRAL) With Shares Advancing 25%

Apr 03
Subdued Growth No Barrier To Epigral Limited (NSE:EPIGRAL) With Shares Advancing 25%

Calculating The Fair Value Of Epigral Limited (NSE:EPIGRAL)

Feb 28
Calculating The Fair Value Of Epigral Limited (NSE:EPIGRAL)
User avatar

Doubling CPVC And ECH Production Will Strengthen Future Prospects

Epigral is expanding production capacity and focusing on high-margin value-added products to enhance earnings and future growth.

Here's Why Epigral (NSE:EPIGRAL) Has Caught The Eye Of Investors

Dec 18
Here's Why Epigral (NSE:EPIGRAL) Has Caught The Eye Of Investors

Epigral Limited's (NSE:EPIGRAL) Shares Leap 29% Yet They're Still Not Telling The Full Story

Jul 04
Epigral Limited's (NSE:EPIGRAL) Shares Leap 29% Yet They're Still Not Telling The Full Story

Epigral Limited (NSE:EPIGRAL) Looks Just Right With A 27% Price Jump

Apr 19
Epigral Limited (NSE:EPIGRAL) Looks Just Right With A 27% Price Jump

Epigral Limited (NSE:EPIGRAL) Soars 28% But It's A Story Of Risk Vs Reward

Feb 23
Epigral Limited (NSE:EPIGRAL) Soars 28% But It's A Story Of Risk Vs Reward

Epigral (NSE:EPIGRAL) Might Be Having Difficulty Using Its Capital Effectively

Feb 21
Epigral (NSE:EPIGRAL) Might Be Having Difficulty Using Its Capital Effectively

Capital Investment Trends At Meghmani Finechem (NSE:MFL) Look Strong

Apr 05
Capital Investment Trends At Meghmani Finechem (NSE:MFL) Look Strong

With EPS Growth And More, Meghmani Finechem (NSE:MFL) Makes An Interesting Case

Sep 28
With EPS Growth And More, Meghmani Finechem (NSE:MFL) Makes An Interesting Case

Meghmani Finechem's (NSE:MFL) Promising Earnings May Rest On Soft Foundations

May 03
Meghmani Finechem's (NSE:MFL) Promising Earnings May Rest On Soft Foundations

収支内訳

Epigral の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NSEI:EPIGRAL 収益、費用、利益 ( )INR Millions
日付収益収益G+A経費研究開発費
31 Dec 2524,1873,3791,3710
30 Sep 2524,6684,0241,3460
30 Jun 2525,0554,3251,3010
31 Mar 2525,5013,5771,2750
31 Dec 2424,4713,4811,2120
30 Sep 2422,7342,9351,1460
30 Jun 2421,2552,5021,0850
31 Mar 2419,2921,9591,0190
31 Dec 2319,6671,9538870
30 Sep 2320,3312,2348710
30 Jun 2321,1042,7708650
31 Mar 2321,8843,5338860
31 Dec 2221,2503,7569240
30 Sep 2220,0933,6828950
30 Jun 2217,9343,2368480
31 Mar 2215,5092,5287680
31 Mar 218,2861,0085360
31 Mar 206,0981,1414410
31 Mar 197,1041,8284820
31 Mar 185,9751,5553710
31 Mar 173,9216651500
31 Mar 163,9826721200

質の高い収益: EPIGRALは 高品質の収益 を持っています。

利益率の向上: EPIGRALの現在の純利益率 (14%)は、昨年(14.2%)よりも低くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: EPIGRALの収益は過去 5 年間で年間10.8%増加しました。

成長の加速: EPIGRALは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: EPIGRALは過去 1 年間で収益成長率がマイナス ( -2.9% ) となったため、 Chemicals業界平均 ( 8.7% ) と比較することが困難です。

株主資本利益率

高いROE: EPIGRALの 自己資本利益率 ( 16.1% ) は 低い とみなされます。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/01 15:33
終値2026/04/30 00:00
収益2025/12/31
年間収益2025/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Epigral Limited 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3

アナリスト機関
null nullBP Wealth Management Private Limited
null nullEmkay Global Financial Services Ltd.
Meet VoraEmkay Global Financial Services Ltd.